nevirapine has been researched along with Stunted Growth in 2 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity." | 7.80 | HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014) |
| "Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity." | 3.80 | HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramokolo, V | 1 |
| Lombard, C | 1 |
| Fadnes, LT | 1 |
| Doherty, T | 1 |
| Jackson, DJ | 1 |
| Goga, AE | 1 |
| Chhagan, M | 1 |
| Van den Broeck, J | 1 |
| Venkatesh, KK | 1 |
| Lurie, MN | 1 |
| Triche, EW | 1 |
| De Bruyn, G | 1 |
| Harwell, JI | 1 |
| McGarvey, ST | 1 |
| Gray, GE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PROMISE EBF: Promoting Infant Health and Nutrition in Sub-Saharan Africa: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV[NCT00397150] | 2,579 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 310 |
| No Intervention | 161 |
The EBF prevalences based on 24-h recall at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 56 |
| No Intervention | 30 |
The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 323 |
| No Intervention | 161 |
(NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 104 |
| No Intervention | 101 |
1 trial available for nevirapine and Stunted Growth
| Article | Year |
|---|---|
Growth of infants born to HIV-infected women in South Africa according to maternal and infant characteristics.
Topics: Adult; Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Epidemiologic Methods; Femal | 2010 |
1 other study available for nevirapine and Stunted Growth
| Article | Year |
|---|---|
HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants.
Topics: Adolescent; Adult; Anti-HIV Agents; Black People; Female; Growth Disorders; HIV; HIV Infections; HIV | 2014 |